Search

Your search keyword '"A. Lambertini"' showing total 21 results
Start Over Author "A. Lambertini" Journal cancer treatment reviews
21 results on '"A. Lambertini"'

1. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis

Author

Schettini, Francesco, Nucera, Sabrina, Pascual, Tomás, Martínez-Sáez, Olga, Sánchez-Bayona, Rodrigo, Conte, Benedetta, Buono, Giuseppe, Lambertini, Matteo, Punie, Kevin, Cejalvo, Juan Miguel, Arpino, Grazia, Vigneri, Paolo, Generali, Daniele, Ciruelos, Eva, Cortés, Javier, Gennari, Alessandra, Muñoz, Montserrat, Vidal Losada, Maria J., Tolaney, Sara M, Prat, Aleix, and Villacampa, Guillermo

Published
2025
Full Text
View/download PDF

2. Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion

Author

Kastora, Stavroula L., Pantiora, Eirini, Hong, Yong Hwa, Veeramani, Meenakshi, Azim, Hatem A, Jr, Chakrabarti, Rima, Geisler, Jürgen, Knoop, Ann, Lambertini, Matteo, Linderholm, Barbro, Meattini, Icro, Partridge, Ann H, Vaz-Luis, Ines, Vorburger, Denise, Yongue, Gabriella, Karakatsanis, Andreas, and Valachis, Antonios

Published
2025
Full Text
View/download PDF

4. Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?

Author

Venanzi, Francesco Maria, Bini, Marta, Nuccio, Antonio, De Toma, Alessandro, Lambertini, Matteo, Ogliari, Francesca Rita, Oresti, Sara, Viganò, Maria Grazia, Brioschi, Elena, Polignano, Maggie, Naldini, Matteo Maria, Riva, Silvia, Ferrara, Michele, Fogale, Nicola, Damiano, Giuseppe, Russo, Vincenzo, Reni, Michele, Veronesi, Giulia, Foggetti, Giorgia, Conforti, Fabio, Bulotta, Alessandra, and Ferrara, Roberto

Published
2023
Full Text
View/download PDF

5. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis

Author

Becherini, Carlotta, Visani, Luca, Caini, Saverio, Bhattacharya, Indrani S., Kirby, Anna M., Nader Marta, Gustavo, Morgan, Gilberto, Salvestrini, Viola, Coles, Charlotte E., Cortes, Javier, Curigliano, Giuseppe, de Azambuja, Evandro, Harbeck, Nadia, Isacke, Clare M., Kaidar-Person, Orit, Marangoni, Elisabetta, Offersen, Birgitte, Rugo, Hope S., Morandi, Andrea, Lambertini, Matteo, Poortmans, Philip, Livi, Lorenzo, and Meattini, Icro

Published
2023
Full Text
View/download PDF

7. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

Author

Schettini, Francesco, Venturini, Sergio, Giuliano, Mario, Lambertini, Matteo, Pinato, David J., Onesti, Concetta Elisa, De Placido, Pietro, Harbeck, Nadia, Lüftner, Diana, Denys, Hannelore, Van Dam, Peter, Arpino, Grazia, Zaman, Khalil, Mustacchi, Giorgio, Gligorov, Joseph, Awada, Ahmad, Campone, Mario, Wildiers, Hans, Gennari, Alessandra, Tjan-Heijnen, Vivianne, Bartsch, Rupert, Cortes, Javier, Paris, Ida, Martín, Miguel, De Placido, Sabino, Del Mastro, Lucia, Jerusalem, Guy, Curigliano, Giuseppe, Prat, Aleix, and Generali, Daniele

Published
2022
Full Text
View/download PDF

19. Fertility and pregnancy issues in BRCA-mutated breast cancer patients

Author

Matteo Lambertini, Isabelle Demeestere, Ornite Goldrat, Michail Ignatiadis, Angela Toss, Lucia Del Mastro, Fedro A. Peccatori, and Hatem A. Azim

Subjects
BRCA, Breast cancer, Fertility, Pregnancy, Young women, 0302 clinical medicine, Nuclear Medicine and Imaging, Medicine, Fertility preservation, Patient group, skin and connective tissue diseases, media_common, education.field_of_study, 030219 obstetrics & reproductive medicine, BRCA1 Protein, Age Factors, Fertility Preservation, General Medicine, Oncology, 030220 oncology & carcinogenesis, Female, Patient Safety, Radiology, Pregnancy Complications, Neoplastic, Needs Assessment, Adult, medicine.medical_specialty, BRCA2 Protein, Breast Neoplasms, Humans, Risk Assessment, Genetic Predisposition to Disease, Mutation, Radiology, Nuclear Medicine and Imaging, media_common.quotation_subject, Population, 03 medical and health sciences, Radiology, Nuclear Medicine and imaging, education, Oncofertility, Gynecology, Neoplastic, business.industry, BRCA mutation, medicine.disease, Pregnancy Complications, Family medicine, business
Abstract

Fertility and pregnancy-related issues represent one of the main areas of concerns for young women with breast cancer. Carrying a germline deleterious BRCA mutation adds additional burden on this regard due to the specific issues that should be considered during the oncofertility counseling of this special patient group. Despite the availability of a growing amount of data in the general breast cancer population on the feasibility and safety of fertility preservation and pregnancy after diagnosis, numerous challenges remain for BRCA-mutated breast cancer patients in whom very limited studies have been performed so far. Therefore, studies aiming to address the specific issues of these patients, including the impact of the mutation on their fertility potential, the safety and efficacy of the different strategies for fertility preservation, and the feasibility of having a pregnancy after diagnosis, should be considered a research priority. The aim of the present manuscript is to perform an in depth overview on the role of BRCA mutations in breast cancer with a specific focus on their impact on reproductive potential, and to discuss the fertility and pregnancy issues faced by BRCA-mutated breast cancer patients. The final goal of this manuscript is to highlight current and upcoming knowledge in this field for trying to help physicians dealing with these patients during oncofertility counseling.

Published
2017

20. Targeted agents for cancer treatment during pregnancy

Author

Fedro A. Peccatori, Matteo Lambertini, and Hatem A. Azim

Subjects
medicine.medical_specialty, medicine.medical_treatment, Abortion, Antibodies, Biological agents, Pregnancy, Placenta, Nuclear Medicine and Imaging, Neoplasms, Monoclonal, medicine, Animals, Humans, Radiology, Nuclear Medicine and imaging, Molecular Targeted Therapy, Intensive care medicine, Malformation, Protein Kinase Inhibitors, Targeted agents, Tyrosine kinase inhibitors, Fetus, Chemotherapy, Neoplastic, business.industry, Cancer, Antibodies, Monoclonal, General Medicine, Cancer during pregnancy, Monoclonal antibodies, Safety, Female, Pregnancy Complications, Neoplastic, Oncology, Radiology, Nuclear Medicine and Imaging, medicine.disease, Preclinical data, Cancer treatment, Pregnancy Complications, medicine.anatomical_structure, Immunology, business, Radiology
Abstract

The last decade has witnessed important advances in the field of managing cancer during pregnancy. However, still limited data is available on the safety of administering targeted agents in pregnant cancer patients. Given the increasing use of targeted agents in clinical practice, it is becoming vital to properly understand how far they can be used in a pregnant patient without compromising the outcome of the fetus. Unlike chemotherapy, monoclonal antibodies are large molecules that require active transport via the placenta to reach the fetus. On the other hand, similarly to chemotherapy, small molecules like tyrosine kinase inhibitors (TKIs) can cross the placenta throughout the pregnancy period. The majority of targeted agents have worrying preclinical data discouraging their use during pregnancy. Multi-TKIs are of particular concern given their potential interference with other vital physiological functions that could be necessary in fetal development. Yet this does not mean that all targeted agents should be avoided completely during pregnancy. The current review provides a critical evaluation on all targeted agents that are currently in clinical use and provides a guide in order to help clinicians counseling their pregnant cancer patients.

Published
2015

21. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.

Author

Lambertini, Matteo, Horicks, Florence, Del Mastro, Lucia, Partridge, Ann H, and Demeestere, Isabelle

Abstract

Survivorship issues are an area of crucial importance to be addressed as early as possible by all health care providers dealing with cancer patients. In women diagnosed during their reproductive years, the possible occurrence of chemotherapy-induced premature ovarian insufficiency (POI) is of particular concern being associated with important menopause-related symptoms, psychosocial issues as well as infertility. Temporary ovarian suppression by administering a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy has been studied to reduce the gonadotoxic impact of chemotherapy thus diminishing the chance of developing POI. Despite more than 30 years of research in both preclinical and clinical settings, the performance of this strategy has remained highly debated until recently. In particular, the potential mechanisms of action for the protective effects of GnRHa during chemotherapy are still not clearly identified. Nevertheless, important novel research efforts in the field have better elucidated the role of this option that is now endorsed for clinical use by several guidelines. This manuscript aims at providing an extensive overview of the literature on the use of temporary ovarian suppression with GnRHa during chemotherapy in cancer patients by addressing its biological rationale, the available preclinical and clinical evidence as well as the still existing grey zones in this field that future research efforts should address. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results